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Background: Statins (HMG CoA reductase inhibitors), in addition to reducing circulating cholesterol and
incidence of coronary heart disease, also have pleiotropic, anti-inflammatory effects. Patients with chronic liver
diseases, non-alcoholic fatty liver disease (NAFLD) or hepatitis C are often excluded from statin therapy because
of adverse effects in a small cohort of patients despite increased cardiovascular risk cholesterol. Ezetimibe, which
inhibits cholesterol absorption by inhibition of Niemann-Pick C1 like 1 (NPC1L1) protein in the brush border of
intestinal cells, has been suggested as a new therapeutic option in these patients.
Methods: Effects of ezetimibe on lipoprotein metabolism, hepatic and intestinal lipid content in guinea pigs, an
animal model with a lipoprotein profile and pattern similar to humans were investigated. In order to investigate a
possible effect of ezetimibe on cholesterol induced inflammation NF-kappaB activation as an indicator for
inflammatory processes in liver and gut tissue was measured.
Results: Lipid enriched diet led to accumulation of lipids in hepatic tissue which caused strong hepatic NF-kappaB
activation. Ezetimibe reduced lipid diet induced increase of circulating cholesterol by about 77% and prevent hepatic
NF-kappaB activation almost completely. In contrast in intestinal cells Ezetimibe, though lowering diet induced
cholesterol accumulation, increased triglyceride content and subsequent NF-kappaB activation.
Conclusion: In summary these data show, that ezetimibe effectively reduced diet induced circulating cholesterol
levels, hepatic lipid accumulation and inflammatory response in our guinea pig model. However this drug elicited a
local inflammatory response in intestinal tissue. Whether these diverse effects of ezetimibe on inflammatory parameters
such as NF-kappaB have clinical relevance remains to be determined.
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Although statins (HMG CoA reductase inhibitors) very
rarely cause clinically significant liver injury, asymptom-
atic elevation in aminotransferases is common [1]. There-
fore patients with chronic liver diseases, non-alcoholic
fatty liver disease (NAFLD) or hepatitis C are often ex-
cluded from statin therapy despite increased cardiovascu-
lar risk [2]. To achieve a relevant reduction of cholesterol
in plasma, cholesterol absorption inhibitor ezetimibe
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has been suggested as an additional therapy to low dose
statins. Combination of low dose statins (10 mg/day) with
administration has even been shown to be more effective
than statin monotherapy [3, 4]. Recent data show that eze-
timibe also reduces insulin resistance, dyslipidaemia and
hepatic fat accumulation in patients with NAFLD [5–7].
Therefore this drug has been suggested as a new thera-
peutic option in these patients. Hepatic fat accumulation
is an essential feature of NAFLD and may stem from diet-
ary fat, from adipocytes via lipolysis and from de novo
lipogenesis. Although fatty liver is thought to be benign,
accumulation of lipids can lead to lipotoxicity resulting in
inflammation, probably due to oxidative processes [8, 9].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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kappaB activation, release of proinflammatory cytokines
and subsequent cell death. Although the extent of inflam-
mation varies considerably in steatohepatitis, in some
cases it may lead to hepatic injury, cirrhosis and hepato-
cellular carcinoma [10].
Ezetimibe inhibits cholesterol absorption as well as its
reuptake via the enterohepatic cycle in the mucosa of
the small intestine without affecting the absorption of
triglycerides or fat-soluble vitamins [11]. The molecular
target of ezetimibe is the Niemann-Pick C1 like 1
(NPC1L1) protein in the brush border of intestinal cells al-
though other proteins may be also involved [12]. NPC1L1
protein is necessary to transport unesterified cholesterol
from the intestine to the endoplasmatic reticulum, where
it is esterified and assembled into chylomicrons particles.
Inhibition of NPC1L1 protein thereby decreases the
amount of cholesterol delivered by chylomicrons to the
liver [13]. However NPC1L1 receptor is also highly
expressed in hepatocytes and is thought to play a role in
regulating biliary cholesterol concentration [14]. This may
explain recent observations, that inhibition of NPC1L1 by
ezetimibe modulates hepatic and metabolic disorders in
rodents [15–17]. However value of studies in animal
models such as mice and rat is limited because LDL is not
the main cholesterol transporting lipoprotein and hepatic
lipid metabolism may differ from humans. Ezetimibe
reduces LDL by about 18–20% which may be effective
reduction in borderline patients, but unfortunately no de-
tailed studies about clinical safety of this drug are available
to date [18].
Statins, which effectively reduce circulating cholesterol,
have been shown to exhibit a wide variety of immunomod-
ulatory effects independent of their lipid lowering effects
[19]. In contrast, pleiotropic effects of ezetimibe are still
under debate. Whereas some studies indicate an anti-
inflammatory effect [20, 21], other studies found no effects
on inflammation [22, 23].
Accordingly this study was designed to determine the
effects of ezetimibe on lipid metabolism, tissue lipid con-
tent and NF-kappaB activation in hepatic and intestinal
tissue of guinea pigs. This animal model was chosen
because its lipoprotein profile, response to statins, hepatic
HMG-CoA reductase activity, and rates of hepatic choles-
terol synthesis are similar to humans [24].
Methods
Biochemicals
All chemicals and biochemicals were obtained from Sigma
Chemie GmbH (München, FRG), E. Merck GmbH (Darm-
stadt, FRG) or Roche (Mannheim, FRG). Bovine serum
albumin was obtained from Behring (Marburg, FRG). Fetal
calf serum was from Gibco Europe Ltd. (Eggstein, FRG).
125I-sodium iodide, DL[2-3H]-mevalonic acid and 14C-cholesteryloleate were purchased from Amersham Buchler
GmbH & Co. KG (Braunschweig, FRG), 3-hydroxyl[3-14C]-
methylglutaryl CoA (HMG-CoA) from Du Pont, NEN
Products (Boston, MA, USA). Ezetimibe [1-(4-fluoro-
phenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-
(4S)-(4-hydroxypropyl)-2-azetidinone] was provided by
Merck, Sharp & Dome Resarch Laboratories (West
Point, PA, USA).
Animal procedures
Male Dunkin-Heartley guinea pigs (300–400 g body
weight) obtained from Charles River, Kisslegg, Germany,
were maintained in a light-cycle room (dark from
7:00 a.m. to 7:00 p.m., light from 7:00 p.m. to 7:00 a.m.)
and had free access to food and water ad libitum. Diets
were prepared as previously described by Conde et al.
[25]. All diets were prepared and pelleted by Fa. ssniff G®
(Germany). Composition of chow diet was as follows:
21% protein, 3% fat, 14% fiber, 8,3% essential minerals,
0,007% vitamin E and 0.015% vitamin C. Cholesterol diet
contained 0,2% cholesterol and 15% fat consisting olive,
palm kernel and safflower oil (1:2:1,8). Ezetimibe diets
were prepared as described above but contained in
addition 0.005% ezetimibe.
After 1 week of adaptation guinea pigs were main-
tained on the indicated diets for further 2 weeks. Animal
groups were as follow: Chow diet (n = 12), Cholesterol
diet (n = 12), Chow diet plus Ezetimibe (n = 4), Choles-
terol diet plus Ezetimibe (n = 8). All experiments were
carried out between 8 and 10 am.
Blood and tissue samples
Blood was obtained by aortic puncture and collected in
tubes containing EDTA. These tubes were centrifuged at
5,000 g for 15 min at 4 °C. Plasma was separated and
stored at 4 °C. Liver tissue was frozen by Wollenberger
technique in liquid N2 [26] and stored at −196 °C for
biochemical analysis. Gut tissue was washed twice with
saline. Liver and gut tissue were frozen immediately in
liquid nitrogen (−180 °C) for immunohistological studies.
Clinical chemistry measures
Cholesterol and triglyceride plasma levels [mg/dl] as well
as aspartate aminotransferase (AST), alanine transaminase
(ALT) and gamma-glutamyl transpeptidase (gGT) activ-
ities in plasma [U/l] were measured with Roche automated
system (Integra 800, Roche diagnostics).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts from gut and liver tissue: Nuclear ex-
tracts were prepared as described by Fukuma et al. [27].
Briefly, tissue was homogenized in homogenizing buffer
(10 mM HEPES-buffer pH 7.6, containing 0.1 mM
EDTA, 15 mM KCl, 2 mM MgCl2, 1 mM DTT, 1 mM
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inhibitor cocktail). This homogenate was centrifuged at
850xg and supernatant was discarded. Cell pellet was
incubated in homogenizing buffer containing 0.2% Igepal
(Sigma, Germany) on ice for 10 min and centrifuged. After
discarding the supernatant pellet was rinsed in homogen-
izing buffer containing 0.25 sucrose, centrifuged for 5 min
at 850 × g and supernatant was discarded. Finally pellet
was suspended in nuclear extraction buffer (50 mM
HEPES, pH 7.9, containing 0.1 mM EDTA, 0.4 mM KCl,
10% glycerol, 1 mM DTT, 0.5 mM PMSF and 1% protease
inhibitor cocktail) and was shaken for 30 min at 4 °C,
centrifuged at 12,000 × g for 5 min. Supernatant (nuclear
extract) was kept frozen at −80 °C.
DNA binding assay: NF-kappaB consensus oligonucleo-
tides GPNFKB-01 L: 5′-AGT-TGA-GGG-GAC-TTT-
CCC-AGG-C-3′ and GPNFKB-02 k: 5′-GCC-TGG-GAA-
AGT-CCC-CTC-3′ (Eurogentec, Belgien) were annealed
and labeled with [alpha-32P]dATP (Amersham Germany)
in the presence of deoxynucleoside triphosphates by
primer extension with the Klenow fragment of DNA poly-
merase I (Roche, Mannheim, Germany). Nuclear proteins
were incubated with 32P labeled oligonucleotide in binding
buffer (10 mM Tris-buffer pH 7.5, containing 50 mM
NaCl, 5 mM MgCl2, 1 mM EDTA, 10% glycerol, 5 μg
bovine serum albumin, 0.2% Nonidet P-40, 4 μg poly-(dI-
dC) und 1 mM DTT) for 15–30 min. DNA bound NF-
kappaB was separated by electrophoresis on 5% acryl/bisa-
crylamid gel in 0.25× Tris borate EDTA buffer (4 °C). Each
lane contained 5 μg nuclear protein and 60,000 CPM. Gels
were dried, exposed to storage phosphor screens, read in a
phosphorimager (Storm, Molecular Dynamics, USA) and
quantified using ImageQuant software (ImageQuant®,
Molecular Dynamics, USA).HMG CoA reductase activity in liver microsomes and LDL
binding to hepatic membranes
Isolation of liver microsomes and incubation of micro-
somes with [14C]-HMG-CoA was performed as de-
scribed by Walli and Seidel [28], with the exception
that [14C]-mevalonolactone was separated from 14C-
HMG-CoA by column chromatography. Lactonised in-
cubates (0.05 ml) were applied to a 0.5 × 5 cm column
containing 100–200 mesh Bio-Rex, chloride form (Bio
Rad, Munich, FRG) which was equilibrated with dis-
tilled water. [14C]-mevalonolactone was eluted with
2 ml of distilled water directly into scintillation vials.
After addition of 10 ml Ultima Gold scintillation fluid
(Packard Instr., Zürich, Switzerland) radioactivity was
measured in a scintillation counter. Binding of LDL to
hepatic membranes was assayed according to Kovanan
et al. [29]. Briefly membranes were isolated from ho-
mogenized liver tissue by ultracentrifugation. Forbinding assay 125I labeled apo-E rich human VLDL was
used as a ligand. Maximal binding affinity was calcu-
lated by scatchard plot analysis.
Lipid content in liver and gut
Tissue lipids were measured according to Carr et al. [30].
14C-cholesteryloleate was added as an internal standard.
Histology
Liver and intestine tissue were removed from animals
under deep anesthesia, quickly blotted free of blood,
weighed, and processed for histology, immunohistology,
and gel shift analysis. Tissue samples, 3–4 μm in thick-
ness, were prepared using cryostat technology (CM1900,
Leica), mounted on poly-L-lysine coated slides, dried at
room temperature for 1 h and stained with oil red for
fat staining. For immunohistology samples were cut
into 1-mm thick slices, immersed in 4% formaldehyde
and then embedded in paraffin. In addition tissue slices
were snap frozen in liquid nitrogen and stored at −80 °C
for further analysis.
Immunohistology
Immunohistochemical staining was done on sections of
paraffin-embedded tissue samples. Primary antibody mouse
anti-human NF-kappaB p50 (Santa Cruz Biotechnology,
USA) was diluted 1:200 with PBS containing 0.05% Tween
and 1% BSA. Biotinylated rabbit anti-mouse immunoglobu-
lins (DAKO, Germany), diluted 1:200 in PBS-BSA served as
a secondary antibody. After 30 min incubation, slides were
washed twice in PBS-Tween for 10 min each. This was
followed by incubation with streptavidin-horse reddish
peroxidase (HRP) (DAKO, Germany) diluted 1:200 for
20 min. Substrate 3-amino-9-ethyl -carbazole (ACE) (0.01%)
containing 0.006% H2O2 was added shortly before use for
colour development. Sections were counterstained with
Harris modified Hematoxylin 1:4 (Sigma, Germany) for
30 s. Slides were examined under light microscope and film
EPY 64 T (Kodak, Germany) was used for photographs.
In order to establish, whether gel shift assay as well as
immunohistology was suitable in the present model, guinea
pigs were treated intraperitoneally with LPS (2 mg/kg body
weight) to induce endotoxinemia and sepsis. Figure 1 shows
gelshift analysis of NF-kappaB activation in liver and gut tis-
sue by EMSA (A) and immunohistology (B). As expected,
LPS activated NF-kappaB in both, liver and intestine tissue.
Statistics
All data are given as means ± standard deviation (SD)
and compared using the Wilcoxon, Mann-Whitney rank
sum test for non-parametric data and t-test for paramet-
ric data. P values < 0.05 were considered as statistically
significant.
Fig. 1 Representative gelshift assays of NF-kappaB in nuclear extracts from (a) and immuncytochemical detection of NF-kappB (b) in liver and
intestine to establish suitability of gel shift assay and immunohistology in this model. Animals were treated with saline or LPS (2 mg/kg body
weight) and killed after the indicated time to obtain liver and intestine tissue. Arrow denotes nuclear NF-kappaB staining
Table 1 Plasma levels of cholesterol and triglycerides in guinea
pigs on chow or cholesterol diet with or without Ezetimibe
Diet n Cholesterol [mg/dl] Triglycerides [mg/dl]
Chow 11 36 ± 18 114 ± 60
Ezetimibe 4 21 ± 5a 72 ± 5
Cholesterol 12 303 ± 91b 302 ± 168b
Cholesterol + Ezetimibe 7 69 ± 28c 281 ± 105b
asignificantly different from Chow-diet, bsignificantly different from Chow and
Ezetimibe diet, csignificantly different from Ezetimibe and Cholesterol diet
Fraunberger et al. Journal of Inflammation  (2017) 14:3 Page 4 of 11Results
Effect of ezetimibe on lipoprotein metabolism
Chow diet together with ezetimibe decreased circulating
levels of cholesterol in guinea pigs by 42% whereas tri-
glyceride levels remained unchanged. Cholesterol diet
increased these levels by ten and three fold, respectively
compared to chow diet. Cholesterol diet in combination
with ezetimibe decreased circulating cholesterol by
about 77% compared to cholesterol diet alone without
altering triglyceride levels (Table 1).
Ezetimibe diet increased HMG-CoA reductase activity
by about 2,6 fold whereas cholesterol diet inhibited
enzyme activity almost completely (Table 2). However
cholesterol enriched diet together with ezetimibe pre-
vent this effect. Maximal binding of apo-E rich VLDL
by isolated hepatic membranes was unaffected by eze-
timibe. Cholesterol enriched diet increased hepaticmembrane binding by about 30%. Cholesterol diet in
combination with ezetimibe did not significantly affect
maximal binding capacity of apo-E rich ligand on
hepatic membranes. In contrast a minimal reduction
of binding affinity as reflected by Km in animals on
chow or cholesterol enriched diet was noted after
ezetimibe treatment.
Table 2 HMG-CoA reductase activity in liver microsomes, Vmax and Km in liver membranes in guinea pigs on chow or cholesterol
diet with or without Ezetimibe
Diet n HMG-CoA reductase [pmol/mg Protein/min] Vmax [μg / mg Protein] Km [μg / ml Medium]
Chow 11 22,2 ± 7,2 1,22 ± 0,21 23,6 ± 4,05
Ezetimibe 4 57,0 ± 28,7a 1,39 ± 0,11 21,56 ± 1,8
Cholesterol 12 1,2 ± 0,5b 1,8 ± 0,45 35,50 ± 7,5
Cholesterol + Ezetimibe 7 25,4 ± 7,0c 1,76 ± 0,35 32,24 ± 7,0
asignificantly different from Chow-diet, bsignificantly different from Chow and Ezetimibe diet, csignificantly different from Ezetimibe and Cholesterol diet
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Cholesterol feeding induced a significant increase of
markers of liver disease such as aspartate aminotransferase
(AST), alanine transaminase (ALT) and gamma-glutamyl
transpeptidase (gGT). In particular ALT, which is recog-
nized as a biochemical marker for fatty liver disease, was
increased about 2 fold. All three parameters returned to
normal circulating values on cholesterol enriched diet
containing Ezetimibe. Ezetimibe alone had no effect on
these markers (Table 3).Effect of ezetimibe on lipid content of liver and intestinal
tissue
Liver
Ezetimibe did not change hepatic content of cholesterol,
triglycerides or phospholipids in animals on chow diet.
In animals fed with cholesterol enriched diet hepatic
cholesterol, triglycerides and phospholipids increased by
5.7, 8.4 and 1.4 fold, respectively. This increase in chol-
esterol and phospholipid content was almost completely
prevented by addition of Ezetimibe. However triglyceride
content in liver tissue was still 2 fold higher when com-
pared to animals on chow diet (Table 4).Intestine
In animals maintained on chow diet containing ezetimibe
no significant changes in cholesterol and phospholipids
content but a 2-fold increase in triglycerides was observed.
Cholesterol diet increased cholesterol, triglyceride and
phospholipid content by 1.54, 3.9 and 1.3 fold, respectively.
Cholesterol diet supplemented with ezetimibe reduced
cholesterol content by 24% but increased triglycerideTable 3 Circulating levels of AST, ALT and y-GT in guinea pigs
on chow or cholesterol diet with or without Ezetimibe
Diet n AST [U/l] ALT [U/l] gGT [U/l]
Chow 12 56 ± 13 40 ± 8 7 ± 2
Ezetimibe 4 64 ± 35 41 ± 17 5 ± 1
Cholesterol 12 143 ± 47a 69 ± 28a 30 ± 27a
Cholesterol + Ezetimibe 8 71 ± 16 47 ± 6 10 ± 3
asignificantly different from Chow diet and Ezetimibe dietcontent by about 45% fold. Phospholipid content remained
unchanged by this diet (Table 5).
Next we stained frozen sections of hepatic and intes-
tinal tissue for neutral lipids (Fig. 2). Cholesterol
enriched diet led to increased neutral lipid staining in
both hepatic and intestinal tissue. Animals maintained
on cholesterol enriched diet containing ezetimibe
showed decreased neutral lipid staining only in hepatic
tissue whereas in intestinal tissue no decrease of neutral
lipids was noted.
Effect of ezetimibe on NF-kappaB activation
Liver
Gel shift assays in nuclear extracts from liver tissue showed
about 4 fold activation of NF-kappaB by a cholesterol
enriched diet (48,337 ± 14,558 vs. 213,650 ± 79,521 arbitrary
units, p < 0.05). Addition of ezetimibe to cholesterol
enriched diet almost completely abolished this NF-kappaB
activation (213,650 ± 79,521 vs. 58,555 ± 25,843 arbitrary
units, p < 0.05). Ezetimibe without cholesterol diet had no
effect on hepatic NF-kappaB activation (Fig. 3a).
Intestine
Ezetimibe alone did not alter NF-kappaB activation
(Fig 3b). However in animals fed on cholesterol diet,
addition of ezetimibe induced approximately 2 fold in-
crease of NF-kappaB activation.
This ezetimibe induced NF-kappaB activation was
confirmed by immunohistological studies (Fig. 4). In
animals on cholesterol diet an increased staining of NF-
kappaB in nuclei of liver cells could be detected, whereas
addition of ezetimibe to cholesterol diet prevented this
effect. In animals fed with ezetimibe alone, no nuclear
staining of NF-kappaB was visible. In intestine tissue
neither cholesterol nor ezetimibe alone induced NF-
kappaB activation. However when ezetimibe was added
to cholesterol diet a strong increase of NF-kappaB stain-
ing was noted in nuclei of intestinal cells.
Discussion
Ezetimibe is a new lipid-lowering agent that inhibits in-
testinal absorption of dietary and biliary cholesterol with
subsequent decrease of about 10–20% in circulating
Table 4 Lipid in content in liver in guinea pigs on chow or cholesterol diet with or without Ezetimibe
Diet n Cholesterol [mg/g] Triglycerides [mg/g] Phospholipids [mg/g]
Chow 10 1,23 ± 0,3 1,65 ± 0,4 9,56 ± 1,7
Ezetimibe 3 1,32 ± 0,2 1,59 ± 0,1 10,38 ± 0,1
Cholesterol 8 7,22 ± 2,1a 13,77 ± 3,1a 13,12 ± 3,1a
Cholesterol + Ezetimibe 7 1,53 ± 0,3 3,85 ± 1,1b 9,73 ± 1,4
asignificantly different from Chow-, Ezetimibe- and Cholesterol + Ezetimibe diet, bsignificantly different from chow, Ezetimibe and cholesterol diet
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However, it has not been shown, whether monotherapy
with ezetimibe has any beneficial effect in CHD patients
[18]. Although combination of low dose statins (10 mg/
day) with ezetimibe administration lowers circulating
LDL-cholesterol, combination of statins with niacin is
superior to ezetimibe in lowering carotid intima thick-
ness [31]. Furthermore some studies raised concerns
about a higher cancer incidence in patients treated with
ezetimibe plus simvastatin [32].
We therefore investigated effects of ezetimibe on
guinea pigs, which are a suitable animal model be-
cause their lipoprotein profile, rates of cholesterol
synthesis and dietary response is similar to humans.
It has been shown, that combinations of high dietary
cholesterol with increased fat content effectively in-
crease circulating LDL cholesterol in this animal
model. Furthermore cholesterol lowering drugs such
as statins strongly reduce the dietary induced LDL
cholesterol levels [24, 25].
In our study we found a 77% reduction of high choles-
terol diet induced circulating cholesterol with Ezetimibe.
Furthermore hepatic HMG-CoA reductase activity, which
was strongly suppressed by cholesterol diet, returned to
control level in ezetimibe treated animals which indirectly
confirms the cholesterol lowering effect of the drug in this
animal model. It is well established that enterocytes derive
their cholesterol by absorption from the intestinal lumen,
intracellular synthesis and uptake of LDL from the plasma.
Under physiological conditions the amount of absorbed
cholesterol by far exceeds new synthesis as well as receptor
mediated uptake from the plasma. Enterocytes takes up
dietary cholesterol and also cholesterol from entero-
hepatic recirculation. In the present study cholesterol
enriched diet increased cholesterol and triglycerideTable 5 Lipid content in gut in guinea pigs on chow or cholesterol
Diet n Cholesterol [mg/g]
Chow 11 1,18 ± 0,2
Ezetimibe 3 0,96 ± 0,3
Cholesterol 12 1,82 ± 0,3a
Cholesterol + Ezetimibe 6 1,39 ± 0,3d
asignificantly different from Chow, Ezetimibe and Cholesterol + Ezetimibe diet, bsign
different from Chow, Cholesterol and Cholesterol + Ezetimibe diet, dsignificantly diffcontent of intestine by 1,5 and 3.9 fold, respectively
(see Fig. 2 and Table 4).
Ezetimibe inhibits NPC1L1 protein resulting in reduc-
tion of micellar cholesterol to the endoplasmatic
reticulum which may cause alteration in lipid distribution
in chylomicrons [12]. High fat diet loads the intestinal
lumen with micellar triglycerides; after entry into entero-
cytes these are converted to triglyceride rich chylomi-
crons. During ezetimibe treatment chylomicron particles
are cholesterol depleted. Whether their transport out of
enterocytes was hampered leading to an intracellular
triglyceride rise remains to be analyzed. In a rare genetic
disease, chylomicrons retention disease, it has been
shown, that assembly of chylomicrons and their delivery
into the circulation may be responsible for their retention
in intestine. These patients accumulate chylomicrons like
lipid droplets containing apoB-48 resulting in a phenotype
similar to the histological findings in this study.
In monkeys as well as in humans it has been shown,
that treatment with ezetimibe reduce cholesterol content
of chylomicrons but did not significantly reduce apo B48
concentrations or kinetics suggesting that ezetimibe re-
duce LDL cholesterol by decreasing delivery of choles-
terol from the intestine to the liver rather than by
reducing chylomicrons particle number [33, 34]. These
effects may have significance in humans, who usually
receive ezetimibe in combination with statins.
Various studies show that ezetimibe does not affect
triglyceride absorption; only minor decreases of circu-
lating triglyceride levels have been reported [35, 36].
In our guinea pig model we found an increased intes-
tinal triglyceride content probably due to chylomicron
retention but a decrease of circulating triglycerides of
by ezetimibe (about 37%) in animals on chow diet,
which however was not statistically significant. Thisdiet with or without Ezetimibe
Triglycerides [mg/g] Phospholipids [mg/g]
1,69 ± 0,8 5,29 ± 0,9
3,07 ± 1,1c 4,29 ± 1,1
6,63 ± 2,3a 6,65 ± 1,9
9,67 ± 2,5b 6,97 ± 1,3
ificantly different from Chow, Ezetimibe and Cholesterol diet, csignificantly
erent from Chow and Cholesteroldiet
Fig. 2 Oil red staining of liver and intestine tissue of guinea pigs maintained on various diets. Animals were fed with the indicated diet for
2 weeks. Oil red staining was performed on frozen liver and intestine sections
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duced chylomicrons remnant cholesterol delivery to
the liver [13].
In animals on cholesterol enriched diet we found a
strong decrease of circulation cholesterol by ezetimibe
but statistically insignificant changes of circulating
triglycerides. These effects may be due to constant influx
of triglyceride rich but cholesterol depleted apoB-48 rich
chylomicrons remnants to the liver which result in
reduced VLDL production and subsequent reduced cir-
culating LDL, which is the main cholesterol carrying
lipoprotein in guinea pigs.Recent reports suggest a potential benefit of ezetimibe
on non-alcoholic fatty liver disease (NAFLD) by improv-
ing hepatic insulin sensitivity and decreasing lipid accu-
mulation and hepatic inflammation [37]. Guinea pigs
maintained on fat enriched diet mimic human NAFLD.
Ezetimibe ameliorates the neutral fat accumulation in
these animals as well as markers of liver damage. Cellular
lipid accumulation may cause lipotoxicity leading to in-
flammatory processes and activation of NF-kappaB and
subsequent release of inflammatory cytokines such as
TNF-a, TGF-b, IL-6 and IL-8 [8, 38–41]. Consistent with
this hypothesis activation of NF-kappaB was observed
Fig. 3 Representative gelshift assays of NF-kappaB in nuclear extracts from liver (a) and intestine (b). Guinea pigs were maintained on the indicated
diets for 2 weeks. Gel shift assays were performed on frozen liver and intestine tissue. Arrow denotes nuclear NF-kappaB band. Quantification
of individual bands was done by ImageQuant software (ImageQuant®, Molecular Dynamics, USA)
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ever in animals receiving this diet in combination with
ezetimibe this activation was prevented. In contrast to
liver tissue, neutral fat accumulation as shown by oil
red staining (see Fig. 2) and triglyceride content inintestinal tissue was further increased by ezetimibe (392%
versus 572% over control (see Table 5). Although triglycer-
ides themselves are probably inert, their hydrolysis to free
fatty acids and diacylglycerol may induce inflammatory re-
sponse. It has been shown that these intracellular fatty acid
Fig. 4 Representative micrograph of Immuncytochemical detection of NF-kappB. Guinea pigs were maintained on the indicated diets for 2 weeks.
Immunhistology was performed on paraffin fixed liver and intestine sections. Arrow denotes nuclear NF-kappaB staining
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the activation of NF-kappa B signaling pathways [42, 43]. In
our study ezetimibe treatment increase hepatic triglyceride
content associated with a significant NF-kappaB activation.
Whether this observation is a direct effect of ezetimibe or
due to the triglyceride accumulation which may have in-
flammatory potential cannot be answered by this study.
Conclusion
The data presented in the present study lead us to con-
clude, that ezetimibe effectively reduced diet inducedcirculating cholesterol levels, hepatic lipid accumulation
and inflammatory response in our guinea pig model. In
contrast this drug elicited a local inflammatory response
in intestinal tissue. Whether these diverse effects of ezeti-
mibe on inflammatory parameters such as NF-kappaB
have clinical relevance remains to be determined.
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